Jiangsu clinical-stage biotech developing drugs for eye diseases and neurological disorders, largely pre-revenue.
Jiangsu clinical-stage biotech developing drugs for eye diseases and neurological disorders, largely pre-revenue.
In one line: A small Chinese ophthalmology/CNS biotech.
Moat: none (IP / patents). Pipeline-stage company whose value depends on unproven clinical trial outcomes.
Headquarters: Nantong, Jiangsu, China · Employees: 497
Size Jiangsu Yahong Meditech (688176.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $854M, the 2467th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.03 on 18 Nov 2026.
Performance Over six months the shares fell 19.8%, against -20.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue grew 14.6% over the last twelve months (peer median +3.6%); the operating margin is -172.0% (peer median 3.6%).
Valuation It trades at 15.3× enterprise value to sales against a peer median of 3.5× (2nd most expensive of 18).
Capital Return on invested capital runs 100.2 points below its cost of capital (8.1% WACC).
Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥320M | CN¥275M | CN¥201M | CN¥13.7M | CN¥26,095 |
| Revenue growth | — | +37% | +1,360% | +52,560% | — |
| Gross profit | CN¥256M | CN¥181M | CN¥126M | -CN¥12.2M | -CN¥16.0M |
| EBITDA | n/a | -CN¥410M | -CN¥394M | -CN¥448M | -CN¥316M |
| Net income | -CN¥529M | -CN¥416M | -CN¥384M | -CN¥400M | -CN¥247M |
| Free cash flow | -CN¥556M | -CN¥431M | -CN¥431M | -CN¥500M | -CN¥269M |
| Capital expenditure | CN¥58.4M | CN¥19.1M | CN¥5.79M | CN¥102M | CN¥26.6M |
| Total debt | CN¥393M | CN¥345M | CN¥130M | CN¥134M | CN¥18.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Jiangsu Yahong Meditech 688176.SS | $854M | -20% | +15% | -172% | 15.3× | n/a |
| Chengdu Kanghong Pharmaceutical 002773.SZ | $2.99B | -1% | -11% | 24% | 3.3× | -3.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688176.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.1% | -8.6% | 2nd lowest of 21 |
| 6-month return | -19.8% | -20.3% | 10th highest of 19 |
| Distance from 52-week high | -44.6% | -40.2% | 8th lowest of 21 |
| Revenue growth (TTM) | +14.6% | +3.6% | 5th highest of 19 |
| Operating margin | -172.0% | 3.6% | 3rd lowest of 19 |
| EV / Sales | 15.3× | 3.5× | 2nd most expensive of 18 |
| ROIC minus cost of capital | -100.2 pp | -2.3 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | 15.3× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 5.8× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | 4.7× | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |